Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
Clinical trial NCT05147220 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05147220
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-16
- Primary completion
- 2026-07-21
- Enrollment
- 1000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.